Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis

Yongsheng, Fang; Wu, Qiang; Zhao, Hua-Lu; Zhou, Yuan; Ye, Lei; Liu, Sheng‐Sheng; Li, Xiao-Xue; Du, Wei‐Dong

doi:10.1080/17474124.2021.1900731

Cited by 18 publications

(12 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When applying the GALAD score (age, sex, AFP, AFP-L3 and DCP), the HCC diagnostic accuracy was even higher [area under curve (AUC) 0.976][ 45 , 46 ]. A recent meta-analysis reported that AFP combined with GP73 (a Golgi specific membrane protein found in epithelial cells of bile ducts) has favorable sensitivity (84%) and specificity (92%) in diagnosing HCC with an AUROC value of 0.93[ 47 ].…”

Section: How Is Afp Measured?mentioning

confidence: 99%

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma

Hanif¹,

Ali²,

Susheela³

et al. 2022

WJG

130

View full text Add to dashboard Cite

Alpha-fetoprotein (AFP) is an oncofetal glycoprotein that has been used as a tumor marker for hepatocellular carcinoma (HCC) in combination with ultrasound and other imaging modalities. Its utility is limited because of both low sensitivity and specificity, and discrepancies among the different methods of measurements. Moreover, its accuracy varies according to patient characteristics and the AFP cut-off values used. Combination of AFP with novel biomarkers such as AFP-L3, Golgi specific membrane protein (GP73) and des-gamma-carboxyprothrombin significantly improved its accuracy in detecting HCC. Increased AFP level could also signify severity of hepatic destruction and subsequent regeneration and is commonly observed in patients with acute and chronic liver conditions and cirrhosis. Hereditary and other non-hepatic disorders can also cause AFP elevation.

show abstract

Section: How Is Afp Measured?mentioning

confidence: 99%

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma

Hanif¹,

Ali²,

Susheela³

et al. 2022

WJG

130

View full text Add to dashboard Cite

show abstract

“…So AFP remains a reliable and first-line marker for shown that reasonable multimarker combinations have better sensitivity and specificity than single markers. 22,23 In this study, univariate and multivariate analysis showed that age, sex, AFP, sAXL, DCP, APRI, and GPR were independent risk factors for HCC progression. We also saw significantly higher serum sAXL, DCP, ARRI, and GPR levels in the HCC group than the LC, VH, and HC groups.…”

Section: Discussionmentioning

confidence: 53%

Diagnostic Efficacy and Possible Underlying Mechanisms of Noninvasive Clinical Markers in Hepatocellular Carcinoma

Fu¹,

Li²,

Chen³

et al. 2023

J Clin Transl Hepatol

View full text Add to dashboard Cite

Background and Aims:In this study, we aimed to evaluate the diagnostic values of alpha-fetoprotein (AFP), soluble AXL (sAXL), des-γ-carboxy prothrombin (DCP), the aspartate aminotransferase-to-platelet ratio index (APRI), and the gamma-glutamyl transpeptidase-to-platelet ratio (GPR) in hepatocellular carcinoma (HCC) and the possible underlying mechanisms of the correlations between them. Methods: We collected serum samples from 190, 128, and 75 patients with HCC, cirrhosis, and chronic viral hepatitis, and from 82 healthy subjects. Serum levels of AFP, sAXL, and DCP were determined, and APRI and GPR values were calculated. Receiver operating characteristic (ROC) curves were used to analyze the diagnostic value of single and combined biomarkers. Results: We detected significant differences between the HCC group and other groups regarding serum AFP, sAXL, DCP, and APRI levels. GPR significantly differed between the HCC group and other groups, except for the liver cirrhosis group. AFP, sAXL, DCP, APRI, and GPR had positive correlations with each other, and AFP showed a higher area under the curve (AUC) and Youden index values, while APRI and DCP showed the highest sensitivity and specificity. Also, when AFP was combined with sAXL, DCP, APRI, and GRP, the highest AUC (0.911) and a higher net reclassification improvement value were obtained compared with those obtained for the individual biomarkers. Conclusions: AFP, sAXL, DCP, APRI, and GPR are independent risk factors for

show abstract

“…In this review, various PTMs, mainly including phosphorylation, glycosylation, acetylation, and methylation of proteins that had diagnostic and prognostic value for HCC were summarized (Fig. 1, Tables 1 and 2 35,37,39,40,[44][45][46][47][48][49][50]54,57,59,60,[64][65][66][67][68][69][70]72,74 ). Some PTMs had clinical value for the therapy of HCC.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and Prognostic Value of Protein Post-Translational Modifications in Hepatocellular Carcinoma

Wang¹,

Wang²,

Wang³

et al. 2023

J Clin Transl Hepatol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common malignant tumor with high incidence and cancer mortality worldwide. Post-translational modifications (PTMs) of proteins have a great impact on protein function. Almost all proteins can undergo PTMs, including phosphorylation, acetylation, methylation, glycosylation, ubiquitination, and so on. Many studies have shown that PTMs are related to the occurrence and development of cancers. The findings provide novel therapeutic targets for cancers, such as glypican-3 and mucin-1. Other clinical implications are also found in the studies of PTMs. Diagnostic or prognostic value, and response to therapy have been identified. In HCC, it has been shown that glycosylated alpha-fetoprotein (AFP) has a higher detection rate for early liver cancer than conventional AFP. In this review, we mainly focused on the diagnostic and prognostic value of PTM, in order to provide new insights into the clinical implication of PTM in HCC.

show abstract

Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis

Cited by 18 publications

References 60 publications

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma

Diagnostic Efficacy and Possible Underlying Mechanisms of Noninvasive Clinical Markers in Hepatocellular Carcinoma

Diagnostic and Prognostic Value of Protein Post-Translational Modifications in Hepatocellular Carcinoma

Contact Info

Product

Resources

About